ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
September 22, 2023 06:35 ET
|
ZyVersa Therapeutics
Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP.This study demonstrated that CKD-induced IL-1β...
Clot Busting Drugs Market to Reach $60 Billion, Globally, by 2032 at 8.2% CAGR: Allied Market Research
July 24, 2023 09:55 ET
|
Allied Market Research
Portland,OR, July 24, 2023 (GLOBE NEWSWIRE) -- Allied Market Research has recently published a report, titled, “Clot Busting Drugs Market by Product (Thrombolytic Drugs, Anti-Platelet Drugs,...
Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023
June 26, 2023 07:00 ET
|
Anthos Therapeutics
Patient-Centric Survey Conducted in Collaborationwith StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology,...
Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab
June 08, 2023 11:10 ET
|
Anthos Therapeutics
Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China...
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
May 09, 2023 09:45 ET
|
Anthos Therapeutics
Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient...
New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023
May 05, 2023 08:00 ET
|
Anthos Therapeutics
Additional presentation spotlights GARDENIA registry design in patientswith atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer...
Atrial Fibrillation Market Worth $20.92 Billion, Globally, by 2028 at 14.11% CAGR | The Insight Partners
April 04, 2023 09:45 ET
|
The Insight Partners
Pune, INDIA., April 04, 2023 (GLOBE NEWSWIRE) -- According to our latest study on "Atrial Fibrillation Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Treatment Type, End User,...
Cardiotonic Agents Market Size to Reach USD 4.5 Bn by 2031 Due to the Rise in Prevalence of Cardiovascular Diseases | TMR Study
April 03, 2023 11:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, April 03, 2023 (GLOBE NEWSWIRE) -- According to the market study by Transparency Market Research, the global cardiotonic agents market was worth USD 732 Million...
Atrial Fibrillation Market Size & Share to Surpass $38.9 Billion by 2028 | Vantage Market Research
March 27, 2023 09:27 ET
|
Vantage Market Research
WASHINGTON, March 27, 2023 (GLOBE NEWSWIRE) -- The global Atrial Fibrillation Market was valued at USD 17.5 Billion in 2022 and is projected to reach a value of USD 38.9 Billion by 2030 at a CAGR...
Global Heparin Calcium Market to Surpass US$ 1,700.8 Million by 2030, Says Coherent Market Insights (CMI)
February 15, 2023 09:15 ET
|
CMI
Burlingame, Feb. 15, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global heparin calcium market is estimated to be valued at US$ 1,370.9 in 2022 and is expected to exhibit a...